Alcohol Septal Ablation Safe and Effective for Hypertrophic Obstructive Cardiomyopathy

Long-term data from a multicenter registry bolster confidence in a less-invasive alternative to surgical myomectomy.

Alcohol septal ablation is a relatively new therapy for hypertrophic obstructive cardiomyopathy, and long-term outcomes data are scarce. In this multicenter, Scandinavian study, investigators report both short- and long-term outcomes of 313 ablation procedures in 279 patients. All patients had a left ventricular outflow tract (LVOT) gradient at rest or during Valsalva maneuver and severe, drug-refractory symptoms.

During the first year of follow-up, ablation reduced the median resting LVOT gradient from 58 mm Hg to 12 mm Hg and the median Valsalva LVOT gradient from 93 mm Hg to 21 mm Hg. Fourteen percent of patients required repeat ablation or myomectomy within 2 years. The proportion of patients with New York Heart Association class III or …

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI